IDEX Corporation (NYSE: IEX) has reported a clear improvement in orders and operating performance, but the stock's rally appears to have priced in much of the expected recovery. At the September 15, 2026 closing price of $222.84, the company's valuation was close to its own historical range. Further gains will depend on whether new orders convert into revenue, earnings and free cash flow.
The central question is no longer whether IDEX's business is improving, but whether the scale of that improvement is sufficient to support the current share price. Second-quarter results provided evidence of a recovery, yet one strong quarter is not enough to establish that the stock is undervalued. Delays in order delivery or uneven demand across end markets would leave investors with limited valuation support.
Specialized components strengthen customer ties
IDEX typically does not sell complete machines. Instead, it supplies pumps, filtration systems, fluid-control products, optical solutions, engineered materials and pneumatic systems that are built into semiconductor manufacturing, water treatment, industrial process-control, medical equipment and emergency-response applications. For customers, replacing a qualified supplier may reduce component costs, but it also requires renewed engineering validation and can increase the risk of equipment failures or production stoppages.
These design-in relationships form an important part of IDEX's business model. Once its components are incorporated into a customer's equipment design, reliability, delivery performance and long-term support often matter more than purchase price alone. The Mott business adds filtration and flow-control products, giving IDEX broader coverage across semiconductor manufacturing applications.
Investment in artificial intelligence is also creating indirect demand through data centers, semiconductors and power infrastructure. IDEX supplies components used in semiconductor production and participates in equipment linked to power generation and cooling. Data-center power, semiconductor, aerospace and defense demand has become an important source of growth for the Health & Science Technologies segment, while municipal water demand supports other parts of the business.
Management said roughly 50% of semiconductor revenue in Health & Science Technologies comes from recurring business. Mott's filtration products have increased the segment's repeat revenue base. Consumables, however, still depend on factory utilization, meaning this revenue stream remains exposed to the economic cycle.
Second-quarter sales rose 5%, with tariff refund adding $0.08
IDEX's organic revenue increased 5% year over year in the second quarter of 2026 to $920.6 million. Adjusted earnings per share were $2.32, compared with GAAP earnings per share of $1.93. Organic orders rose 28%, while free cash flow reached $177 million.
Organic sales in Health & Science Technologies increased 12%, driven mainly by data-center power, semiconductor, aerospace and defense activity. Municipal water demand supported the company's other businesses, but industrial markets were uneven. The results therefore do not indicate that all end markets recovered at the same pace.
The earnings figures also require further separation of recurring and non-recurring factors. A tariff refund contributed $0.08 to quarterly adjusted earnings per share. Because that benefit may not recur, it has not been included in forward estimates. The quarter's entire improvement in margins, or even most of it, should not be attributed automatically to operating efficiency.
Order growth likewise needs to be tested through delivery. Some customers have already booked products scheduled for shipment in 2027, providing a degree of future sales visibility. Even so, time is required between an order, production, shipment, revenue recognition and cash collection. The key indicators will be the pace of shipments, the actual profitability of the orders and the company's ability to convert completed sales into cash.
Forecast calls for $9.80 in 2027 adjusted EPS
The base case forecasts adjusted earnings per share of $8.80 for this year, within management's revised guidance range of $8.70 to $8.85. Revenue is projected at approximately $3.95 billion next year, about 7% above the current-year estimate.
This outlook does not require a broad recovery across every industrial market, nor does it assume an acquisition that has not been announced. Earnings growth is expected to come mainly from higher revenue, the absorption of fixed engineering and manufacturing costs, and continued emphasis on higher-value customers and applications.
The model estimates that IDEX's consolidated adjusted EBITDA margin will reach 28% next year, up from an estimated 27.2% this year. After depreciation, non-acquisition-related amortization, interest and taxes, and assuming modest net share reductions, that margin would support adjusted earnings per share of approximately $9.80.
The forecast excludes any new tariff refund and assumes that IDEX increases capital spending to support higher production volumes. In other words, it relies on organic revenue growth and operating improvement rather than assuming that the current order backlog will automatically generate an equivalent increase in profit. Performance may also diverge sharply between businesses, with some units growing quickly while others remain stable.
Valuation is near its historical average
Based on adjusted earnings, IDEX trades at approximately 26.3 times current earnings, close to its five-year average of about 27 times. Interest rates, the company's business mix and expectations for future growth could all change how the market assesses an appropriate multiple.
Peer valuations show a wide range. Dover Corporation trades at roughly 18.6 times adjusted earnings, ITT Inc. at about 25.9 times and Pentair at approximately 11.8 times. Dover and ITT also operate in engineered products and fluid handling, but their business profiles differ. Dover runs a diversified industrial franchise portfolio, while ITT has greater exposure to aerospace and is integrating its recent SPX Flow acquisition. Pentair is dealing with inventory and distribution-channel issues, so its lower multiple is not a direct benchmark for IDEX.
IDEX's specialized components, design-in relationships and customer retention may justify a premium to some industrial companies. However, acquisition-related expenses remain an economic cost to the business even when they are excluded from adjusted earnings. Valuation should therefore not be assessed on adjusted measures alone.
Applying a 23-times multiple to next year's forecast earnings produces a value of approximately $225 per share, close to the current price of $222.84. That multiple already includes a premium for business quality while retaining a discount for cyclical exposure. The current price therefore appears to assume that orders convert smoothly and margins improve. Even if operations meet relatively favorable assumptions, the additional upside may remain limited.
Orders, capacity and cash conversion remain key tests
One of IDEX's main variables is whether customer commitments align with the company's actual capacity. If data-center projects slow, semiconductor capital spending weakens or customers reduce purchases because inventories are too high, orders could be deferred and the backlog could take longer to convert into revenue.
Execution is equally important. Acquisitions may give IDEX more technologies and products, potentially expanding the range of items customers buy from the company. Integrating those technologies into existing products requires employee time and can put pressure on manufacturing processes. Completing an acquisition does not by itself demonstrate that the expected return will be achieved. Because IDEX's relationships with customers are long-term and highly specialized, consistent service and product reliability matter more than any single shipment. Losing an important design-in position could have a greater effect than missing one batch of deliveries.
Multiple compression is another risk to the valuation case. Even if IDEX delivers the current-year earnings expectation of about $8.80 per share, a market multiple of 20 times would imply a value of roughly $176 per share. Strong finances and technically specialized products would not fully shield the stock from a reassessment of its earnings multiple.
The quality of the recovery will be clearer if recurring revenue continues to grow, deliveries improve, capital spending remains controlled and earnings translate into free cash flow. If IDEX expands capacity substantially without a corresponding improvement in cash generation, the current share price will leave less room for execution shortfalls.